UnknownPhase 1

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

China113 participantsStarted 2022-01-18

Plain-language summary

To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Able to understand and willing to sign the ICF.
. Aged 18 to 75 years.
. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
. Life expectancy at least 12 weeks.
. Adequate bone marrow, liver and kidney function.

Exclusion criteria

. Toxicity associated with previous antitumor therapy not recovered to ≤CTCAE grade 1；
. Previous treatment with anti-CSF1R therapy and have progressive disease;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Occurrence of Dose-Limiting Toxicities(DLTs)

Timeframe: up to 33 days

Maximum tolerated dose (MTD)

Timeframe: up to 12 months

Recommended phase II dose (RP2D)

Timeframe: up to 12 months

Trial details

NCT IDNCT05277454

SponsorHutchison Medipharma Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-06-28

Contact for this trial

Cindy Hua

+86 21 2067 3221 cindyh@hutch-med.com

View on ClinicalTrials.gov More Advanced Malignant Solid Tumors trials